AMG 317

Drug Profile

AMG 317

Alternative Names: AMG-317; Anti-IL-4R - Amgen; Anti-interleukin-4 receptor antibody - Amgen

Latest Information Update: 30 Mar 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Class Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 26 Mar 2008 AMG-317 is still in phase II trials for asthma in the US
  • 18 Mar 2008 Pharmacokinetics, adverse events and pharmacodynamics data from two Phase-I trials and adverse events data from a Preclinical Trial in Asthma presented at the 64th Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI-2008) ,,
  • 31 Dec 2004 Phase-I clinical trials in Asthma in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top